Tissue transglutaminase: a new target to reverse cancer drug resistance - Wikidata - wikimedia - TriplyDB

Tissue transglutaminase: a new target to reverse cancer drug resistance

Tissue transglutaminase: a new target to reverse cancer drug resistance

http://www.wikidata.org/entity/Q36503511

about

Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment Transglutaminase regulation of cell function.TGM2: a cell surface marker in esophageal adenocarcinomas.Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway.Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.Transglutaminase 2 in cancer.TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF βTrCP-mediated eEF2K degradation.Prognostic role of tissue transglutaminase 2 in colon carcinoma.Effect of retinyl acetate on transglutaminase 2 activity in carcinogen treated rat liver.Transglutaminase 2, a double face enzyme.Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells

P2860

Q26824316-C8150316-3A2D-408F-BC3A-FF50B0E6E1AA Q28550149-1C31BBEB-4CB5-41B7-9160-929A49082B5C Q33707936-8BEAE988-6971-4297-BD34-708EC7C65D68 Q34219975-1E7B6B8B-8A9E-4306-955C-AAC71537EEC2 Q34489967-BFC1DF82-37EB-40A2-90B0-28C710599302 Q35164379-6D895376-11B5-45BE-8DC8-37A1CF44D784 Q35858675-BEDAD936-3034-42F6-8A73-AA593910BA9A Q36022262-E8457969-0559-4883-B8BE-700E45F12933 Q37745215-BE811E26-D720-4916-83E8-29FBEB8BA553 Q38648421-F5327F5C-8E40-465C-A71B-D0766136D4B8 Q38734433-7E4D4776-9EFF-42B5-BD67-E47A378F6737 Q39268578-7CBD9508-2059-40E4-BADF-62100484FAA0 Q42378457-D016C6F7-6D9C-4C97-BCCD-EE5D51C49DD1 Q51515881-3948A46F-5FFE-4DED-983F-A6428F4492C8 Q52874453-2A57A334-6964-4BC0-8FFA-4F13692E0B92 Q54433849-C2299004-0F9D-4CE6-936B-03DF948FDC0F Q57818345-526CD417-2141-4022-AA6C-96DAEFE08525 Q57821053-1A78922E-05D6-44EA-BF2D-87322E3B1D73

P2860

Tissue transglutaminase: a new target to reverse cancer drug resistance

http://www.wikidata.org/entity/Q36503511

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Tissue transglutaminase: a new target to reverse cancer drug resistance

@ast

Tissue transglutaminase: a new target to reverse cancer drug resistance

@en

type

label

Tissue transglutaminase: a new target to reverse cancer drug resistance

@ast

Tissue transglutaminase: a new target to reverse cancer drug resistance

@en

prefLabel

Tissue transglutaminase: a new target to reverse cancer drug resistance

@ast

Tissue transglutaminase: a new target to reverse cancer drug resistance

@en

P1433

Q36503511-53B275AB-E719-47A8-AE26-9C806A13F4AB

P1476

Q36503511-9A97B3B8-3244-4206-8626-6F2D3C2262C8

P2093

Q36503511-437B04E9-AC1E-4217-8FB2-5A6CACBC29CB

Q36503511-C994E0FE-C026-41E3-806E-ED2352A6DDAC

P2860

Q36503511-01818B59-9EAE-4366-A84B-C90200AE63BA

Q36503511-044BD6B6-65E2-4210-B835-027EA66FAC36

Q36503511-046CCAFA-FF05-4B65-B91A-F337DE337CF4

Q36503511-16B40B82-432E-466E-A3A0-750612AD2FFE

Q36503511-16D8DD14-B623-46DC-9ECD-36A4A40738E9

Q36503511-178808BE-A00F-4FF4-924E-F0E0380F167A

Q36503511-18EEDE22-6E49-4A3F-9856-D75C0A4ED86D

Q36503511-1A4A4F65-F6A5-4E57-9FC2-7D3A92AE439B

Q36503511-1D3575B9-3E6C-4AFB-B174-9474F5C37BFC

Q36503511-1DD23AAA-0CFA-4C95-AA92-839F5B34250A

P2888

Q36503511-9ECA3A4A-7C35-40AB-99DA-4E0A63525677

P304

Q36503511-65D02014-F491-433B-B8AA-48144F6BDDA0

P31

Q36503511-18C50F00-B022-41B6-9BB4-E753196AE0CA

Q36503511-CD85DDC2-C40F-4C9B-A84D-0C9D407B78AF

P356

Q36503511-468C3A52-AD41-44FC-A229-2957AAEF38C3

P433

Q36503511-769D1D1E-D058-4916-B522-8DBF932D9904

P478

Q36503511-833787FF-FF42-49B5-B126-B176244472D5

P50

Q36503511-78C1262E-A73E-4937-AA5E-BA59AC6259FC

P577

Q36503511-815700E0-BE45-4D30-9DCB-B143CD8F9690

Q36503511-DFDC5532-6A25-4B2E-9C2A-FD6994C7161A

P5875

Q36503511-3CFC88CC-1966-4B43-B5C0-9FA4A4C03C79

P698

Q36503511-21E3968A-3A20-4978-891B-324B57C6E69E

P921

Q36503511-2327FCE4-84C8-4B95-98D3-F1A0DDB74DFC

Q36503511-FB84BADB-A2A9-4231-A0E9-416772ACE95C

P932

Q36503511-A7A31CE0-24B0-4329-A814-5B0BFB618E7B

P356

S00726-011-1167-9

P1433

P1476

Tissue transglutaminase: a new target to reverse cancer drug resistance

@en

P2093

Alfredo Budillon

http://www.w3.org/2001/XMLSchema#string

Elena Di Gennaro

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway

Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin

Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells

Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells

Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia

Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.

Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.

Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.

P2888

s00726-011-1167-9

P304

63-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00726-011-1167-9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Carmine Carbone

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51843305

http://www.w3.org/2001/XMLSchema#string

P698

22130737

http://www.w3.org/2001/XMLSchema#string

P921

P932

3535412

http://www.w3.org/2001/XMLSchema#string